However, in contrast to these early changes in animals, our observations in established human prostatic cancers are not easily compatible with the classic (and oversimplistic) enhancer competition model, as we did not observe a consistent correlation between methylation patterns of the IGF2 ICR and LOI status, nor with expression of either IGF2 or miR‐675/H19. This evidence concerns the gene IGF2 and prostate cancer.